Neurocrine Biosciences
NBIX
#1416
Rank
A$19.33 B
Marketcap
$191.01
Share price
1.42%
Change (1 day)
13.37%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : A$0.38 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is A$0.38 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$0.62 B62.76%
2022-12-31A$0.38 B-36.4%
2021-12-31A$0.60 B13.29%
2020-12-31A$0.53 B-24.24%
2019-12-31A$0.70 B28.33%
2018-12-31A$0.55 B16.48%
2017-12-31A$0.47 B
2009-12-31A$12.83 M-41.19%
2008-12-31A$21.82 M1183.98%
2007-12-31A$1.69 M-97.5%
2006-12-31A$68.04 M-16.18%
2005-12-31A$81.18 M-4.99%
2004-12-31A$85.45 M74.33%
2003-12-31A$49.01 M248.02%
2002-12-31A$14.08 M26.39%
2001-12-31A$11.14 M60.99%
2000-12-31A$6.92 M46.72%
1999-12-31A$4.71 M-3.71%
1998-12-31A$4.89 M99.5%
1997-12-31A$2.45 M21.93%
1996-12-31A$2.01 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$1.12 B 195.49%๐Ÿ‡บ๐Ÿ‡ธ USA
A$11.54 B 2,923.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$0.89 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
A$47.27 B 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
A$107.29 B 27,996.26%๐Ÿ‡บ๐Ÿ‡ธ USA
A$104.32 B 27,217.82%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.43 B 13.46%๐Ÿ‡บ๐Ÿ‡ธ USA
A$28.21 M-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA